Board Committee Changes

GlaxoSmithKline PLC 28 March 2008 Issued - Friday 28th March 2008 GlaxoSmithKline plc Announces Changes to Board Committee The Board has appointed Mr H Lawrence Culp and Sir Robert Wilson members of the Nominations Committee with immediate effect. A table showing the membership of the Board and its committees is attached. S M Bicknell Company Secretary 28th March 2008 ________________________ Board and Committee Membership with effect from 28th March 2008 Sir Christopher Gent Chairman Sir Ian Prosser Senior Independent Non-Executive Director Dr J-P Garnier Chief Executive Officer Mr Andrew Witty Executive Director, Chief Executive Officer Designate Mr Julian S Heslop Chief Financial Officer Dr Moncef Slaoui Executive Director, Chairman, Research & Development Mr Chris Viehbacher Executive Director, President, US Pharmaceuticals Professor Sir Roy Anderson Independent Non-Executive Director Dr Stephanie Burns Independent Non-Executive Director Mr H Lawrence Culp Independent Non-Executive Director Sir Crispin Davis Independent Non-Executive Director Sir Deryck Maughan Independent Non-Executive Director Dr Dan Podolsky Independent Non-Executive Director Dr Ronaldo Schmitz Independent Non-Executive Director Mr Tom De Swaan Independent Non Executive Director Sir Robert Wilson Independent Non-Executive Director Board Committee Committee Chairman Members Audit Mr Tom De Swaan Sir Deryck Maughan Dr Dan Podolsky Sir Ian Prosser Dr Ronaldo Schmitz Sir Robert Wilson Remuneration Sir Robert Wilson Mr H Lawrence Culp Sir Crispin Davis Sir Christopher Gent Dr Ronaldo Schmitz Nominations Sir Christopher Gent Mr H Lawrence Culp Sir Ian Prosser Dr Ronaldo Schmitz Sir Robert Wilson Corporate Responsibility Sir Christopher Gent Dr Stephanie Burns Sir Ian Prosser Dr Dan Podolsky Mr Tom de Swaan This information is provided by RNS The company news service from the London Stock Exchange

Companies

GSK (GSK)
UK 100

Latest directors dealings